Europe Biopsy Devices Market to Surpass US$ 1.13 Billion by 2033 Amid Rising Cancer Cases and Tech Advancements

Europe Biopsy Devices Market Analysis

The European biopsy devices market is expected to expand from US$672.6 million in 2024 to US$1,137.2 million by 2033, growing at a CAGR of 6.01%. The most important drivers are an increase in cancer cases, the evolving nature of biopsy technologies, and an increased demand for less invasive treatments, coupled with enhanced diagnostic efficiency and the application of image-guided techniques.

Access full report: https://www.renub.com/europe-biopsy-devices-market-p.php

Europe Biopsy Devices Market

Biopsy instruments are medical devices specifically employed to take tissue samples from the body for diagnostic examination. In Europe, these instruments are important in the early diagnosis and identification of diseases, most importantly cancer. Biopsy procedures enable healthcare workers to view tissue under a microscope, enabling them to determine whether or not there is disease and what kind of disease.

Standard biopsy techniques involve fine needle aspiration, core needle biopsy, and image-guided biopsies that use ultrasound or CT scans to provide greater accuracy. The increasing prevalence of cancer throughout Europe has resulted in a growing need for these devices since timely and precise diagnoses are critical for successful treatment planning.

Moreover, progress in biopsy technology, such as minimally invasive methods, has enhanced patient comfort and minimized recovery periods. These factors keep the European biopsy devices market growing, enabling substantial improvement in patient care and outcomes in the region.

Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=europe-biopsy-devices-market-p.php

Trends in the Europe Biopsy Devices Market

Increased Demand for Minimally Invasive Biopsy Procedures

The Europe biopsy devices market is observing increasing demand for minimally invasive procedures owing to their short recovery time, decreased complication risk, and patient comfort. Technologies such as vacuum-assisted and needle-based biopsies are being increasingly preferred in hospitals and diagnostic centers. This trend can be more clearly seen in the diagnosis of breast, lung, and prostate cancers, wherein accuracy and less tissue damage are important. The trend towards minimally invasive methods is driving manufacturers towards developing devices that are both precise and patient-centered procedural strategies. May 2024, Hologic, Inc. made available the 7-gauge needle for the Brevera Breast Biopsy System across Europe, adding to the family of Brevera Disposable Biopsy Needles for radiologists.

Integration of Imaging Technologies with Biopsy Devices

One of the most important trends in the market is the convergence of sophisticated imaging modalities, including MRI, CT, and ultrasound, with biopsies. Image-guided biopsies improve accuracy by allowing for accurate lesion localization and targeted tissue acquisition. This method is increasingly employed in oncology to enhance diagnostic consistency and minimize repeat procedures. European diagnostic centers and hospitals are investing in image-guided systems to deliver improved clinical outcomes. The trend is in line with the increasing adoption of precision medicine and sophisticated cancer diagnostic methodologies. Feb 2025, Royal Philips reported that its Radiology Operations Command Center Console has been certified for remote scanning by EU Medical Device Regulation (MDR). This innovation enables experienced radiologists to guide technologists in real-time, remotely operating scans to provide good-quality images for enhanced diagnostic confidence and patient care.

Increased Demand for Disposable and Single-Use Biopsy Instruments

Increased emphasis on infection control and safety has promoted the use of disposable and single-use biopsy instruments in Europe. These instruments minimize the risk of cross-contamination among patients while maintaining constant performance in diagnostic testing. The COVID-19 pandemic also boosted the demand for single-use devices because of increased sensitivity to hygiene and safety procedures. Companies are reacting with sustainable, affordable disposables that satisfy clinical and regulatory needs. This trend is likely to persist as hospitals focus on infection prevention and procedural effectiveness.

Growth of Robotic and Automated Biopsy Solutions

Robotic and automated biopsy devices are increasingly popular in Europe as the healthcare industry looks to attain greater accuracy and efficiency in the sampling of tissue. Robotic-assisted systems provide enhanced targeting for minor or difficult-to-access lesions, lowering operator dependence and improving reproducibility. Automation also reduces procedure time and alleviates patient discomfort. These machines are especially useful in complicated cancer diagnostics, such as prostate and lung biopsies. With healthcare centers adopting digital and robotic technologies, the movement towards automated biopsy equipment is likely to gather pace, redefining the market in the next few years. February 2023. Euformatics, along with ViennaLab Diagnostics and Oncompass Medicine, has been awarded one of four Phase 1 contracts to create a sustainable liquid biopsy diagnostic solution based on DNA and RNA profiling for cancer patients. This project falls under the OncNGS pre-commercial procurement and consists of a consortium of leading European hospitals in Germany, France, Italy, Spain, and Belgium. Growth Drivers in the Europe Biopsy Devices Market.

Get Customization in the Report: https://www.renub.com/request-customization-page.php?gturl=europe-biopsy-devices-market-p.php

Rising Cancer Prevalence Throughout Europe

The increasing cancer incidence continues to be one of the main growth drivers for the biopsy devices market in Europe. As cancers such as breast, lung, and colorectal increase in frequency, the need for effective diagnostic techniques has risen. Biopsies remain the gold standard for malignancy confirmation, which has compelled hospitals and diagnostic centers to use advanced equipment. National cancer screening campaigns and enlightenment programs in the EU further contribute to market expansion. The increased patient base, along with the need for accurate and early diagnosis, continues to stimulate demand for innovative biopsy solutions. Europe had 4,471,422 new cancer cases in 2022, with an overall risk of 27.9% by age 75. Males accounted for 2,359,303 cases (31.9% risk), and females accounted for 2,112,119 cases (24.7% risk). Northern and Western Europe recorded the highest rates, at 374.7 per 100,000 (34.9% risk) in Denmark, probably due to improved screening and health care.

Technological Advances Increasing Diagnostic Accuracy

Ongoing developments in biopsy instruments, such as the incorporation of imaging guidance, robotic aid, and vacuum assistance, are greatly enhancing diagnostic performance. These developments enable clinicians to achieve high-quality tissue samples with reduced invasiveness and fewer error rates. Image-guided and automated systems also minimize the necessity for repeated procedures, thereby increasing efficiency and patient safety. European health care providers continue to invest in these innovative technologies to keep up with the growing emphasis on precision medicine. Following this, technology-based advancements continue to be a key driver of market growth. In September 2024, to enhance testing for microsatellite instability (MSI) in patients with colorectal cancer, Owkin, an innovative biotechnology company, successfully released MSIntuit CRC, a creative AI diagnostic device.

Favorable Healthcare Infrastructure and Reimbursement Policies

Europe's strong healthcare base and supportive reimbursement policies fuel the uptake of biopsy devices. Advanced medical systems in countries like Germany, France, and the UK afford extensive access to diagnostic technologies via public and private healthcare. Reimbursement for the biopsy procedure incentivizes both patients and health practitioners to access early diagnostics. Further, investment in contemporary hospitals and diagnostic centers throughout Europe facilitates the purchase of state-of-the-art devices. This robust healthcare platform guarantees that the market keeps growing steadily with rising procedural volumes.

Increased Adoption of Ambulatory and Outpatient Diagnostic Services

The trend towards ambulatory and outpatient diagnostic services in Europe is driving the biopsy devices market. Patients are increasingly opting for faster, less painful procedures that enable them to be discharged the same day, and healthcare systems promote these models to keep costs and hospital utilization in check. Needle-based and minimally invasive biopsy equipment are a good fit in this direction, enabling effective collection of samples outside the hospital environment. Portable and disposable biopsy options are useful to ambulatory diagnostic companies as well, suitable for urban and rural clinics. This increased trend towards outpatient diagnosis further consolidates the market demand.

Europe Biopsy CT Scan Devices Market

The market for biopsy CT scan devices in Europe is growing because the demand for accurate, image-guided tissue sampling in cancer and chronic disease diagnosis is increasing. CT-guided biopsy devices enable physicians to access deep or small lesions that are hard to reach with standard techniques, providing higher diagnostic confidence. Hospitals and specialized diagnostic centers in Europe are increasingly using CT-based biopsy systems to achieve higher accuracy with reduced patient risk. As image quality and procedural effectiveness are enhanced by technological advancements, the CT-guided biopsy device market is expanding, especially in oncology applications in the region.

Overview of the Biopsy Devices Market in Germany

Germany is one of the biggest markets for biopsy devices in Europe due to its sophisticated healthcare infrastructure and high rate of use of advanced diagnostic technologies. The nation's high emphasis on cancer screening initiatives, coupled with an increasing elderly population, fuels rising biopsy procedures. German hospitals and diagnostic centers employ combinations of minimally invasive, image-guided, and automated biopsy solutions to maximize precision and efficiency. Favorable reimbursement policies and constant investments in medical technology further consolidate the market. With precision medicine and early diagnosis picking up steam, Germany continues to be a principal hotspot for biopsy device expansion in Europe. March 2022, Illumina released its TruSight oncology test, which analyzes numerous tumor genes and biomarkers. San Diego-based Illumina's CE-marked TruSight test is available throughout the Europe.

Contact Us:

Company Name: Renub Research
Contact Person: Rajat Gupta
Phone No: (D) +91-120-421-9822 (IND)
Email: rajat@renub.com

About the Company:

Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.

This release was published on openPR.